capecitabine has been researched along with Cancer of Duodenum in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
Authors | Studies |
---|---|
Amano, T; Araki, M; Egawa, S; Hayashi, Y; Hirao, M; Hiyama, S; Iijima, H; Inoue, T; Iwatani, S; Kinoshita, K; Kizu, T; Komori, M; Mizushima, T; Morii, E; Murata, J; Nagaike, K; Ogawa, H; Okuda, Y; Otake, Y; Sakakibara, Y; Shinzaki, S; Sugimoto, A; Takahashi, H; Takehara, T; Tani, M; Tashiro, T; Tsujii, Y; Yamaguchi, S; Yoshihara, T | 1 |
Ichikawa, H; Ishikawa, H; Kano, Y; Kobayashi, T; Miura, K; Muneoka, Y; Nakano, M; Sakata, J; Shimada, Y; Tajima, Y; Takizawa, K; Toshikawa, C; Ueki, H; Wakai, T | 1 |
Cunningham, SC; Gormley, PE; Iacobuzio-Donahue, CA; Kern, SE; Patel, K | 1 |
Bai, L; Guo, XC; Mao, ZY; Su, D; Wang, LJ; Zhang, TT | 1 |
Kirii, Y; Miyamoto, M; Takagi, H | 1 |
Jadhav, P; Rogers, JE; Shroff, R | 1 |
6 other study(ies) available for capecitabine and Cancer of Duodenum
Article | Year |
---|---|
Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Duodenal Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; Jejunal Neoplasms; Leucovorin; Male; Organoplatinum Compounds; Prognosis; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A | 2021 |
[A Case of Long-Term Survival with Multidisciplinary Treatment after Surgery for Duodenal Cancer with Left Supraclavicular Lymph Node Metastasis].
Topics: Aged; Capecitabine; Duodenal Neoplasms; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Oxaliplatin; Positron Emission Tomography Computed Tomography | 2022 |
Are we systematically under-dosing patients with fluorouracil?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Duodenal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2015 |
Retrospective analysis of 119 small bowel adenocarcinoma in Chinese patients.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; China; Deoxycytidine; Disease-Free Survival; Duodenal Neoplasms; Duodenum; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
[A case of primary duodenal cancer recurrence successfully treated with CapeOX therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Duodenal Neoplasms; Fatal Outcome; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreaticoduodenectomy; Peritoneal Neoplasms; Recurrence | 2014 |
A Case Report-Stevens-Johnson Syndrome as an Adverse Effect of Capecitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Duodenal Neoplasms; Humans; Male; Middle Aged; Pancreatic Neoplasms; Stevens-Johnson Syndrome | 2018 |